Allogene reports 31% response rate in renal cancer trial

Source and reference

Journal of Clinical Oncology, according to a press release statement issued Wednesday. The company’s stock closed at $1.85, down 12.7% over the past week, though shares remain up 35% year-to-date. With a market capitalization of $639 million, the clinical-stage biotech maintains a strong current ratio of 9.65. The trial evaluated ALLO-316, an investigational allogeneic CAR T therapy targeting CD70, in 51 patients with Stage IV renal cell carcinoma. Of these, 46 received ALLO-316 with a median follow-up of 28.8 months. In the Phase 1b expansion cohort, 20 patients received ALLO-316 at 80 million CAR T cells following standard lymphodepletion. All patients had disease resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor, with 82% having received two or more prior TKIs. Among 16 patients with high CD70 expression (tumor proportion score of 50% or greater)...